Article Text

AB0182 In vitro characterization of dermal fibroblasts from systemic sclerosis patients
  1. R Brizzolara1,
  2. P Montagna1,
  3. S Soldano1,
  4. AC Trombetta1,
  5. B Ruaro1,
  6. A Sulli1,
  7. S Scabini2,
  8. E Stratta2,
  9. V Smith3,
  10. M Cutolo4
  1. 1Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, IRCCS San Martino
  2. 2Oncologic Surgery, Department of Surgery, IRCCS San Martino IST, Genoa, Italy
  3. 3Department of Rheumatology, Ghent University Hospital, Ghent, Belgium
  4. 4Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Genoa, Italy


Background Systemic sclerosis (SSc) is characterized by progressive fibrosis of the skin and/or internal organs. Skin fibrosis is mainly due to the excessive production of extracellular matrix (ECM) proteins from dermal activated fibroblasts. The high amounts of transforming growth factor-beta (TGFbeta) production induce fibroblast proliferation and their transition into profibrotic myofibroblasts. Consequently, the increased presence of alpha-smooth muscle actin (alpha-SMA)-positive myofibroblasts in affected tissues is associated with fibrotic tissue remodelling, that characterize SSc [1–4].

Objectives To characterize dermal fibroblasts from SSc patients by evaluating the gene expression of specific phenotypic and profibrotic markers: fibrillar collagen type I (COL I), fibronectin (FN), fibroblast-specific protein 1 (S100A4), TGFbeta and alpha-SMA (marker of myofibroblasts).

Methods Human dermal fibroblasts were obtained by skin biopsy from affected areas of 6 active lcSSc patients after written informed consent and approval of medical ethics committee. SSc patients fulfilled the new EULAR/ACR criteria for SSc and they were treated only with various vasodilators (no severe clinical SSc complications were present at the time of skin sampling). Human SSc dermal fibroblasts were cultured up to 80% of confluence and at the third to fifth subpassages were used for experiments. Total RNA was extracted and quantitative real-time PCR (qRT-PCR) was performed to evaluate the gene expression of relevant fibroblast markers: COL I, FN, S100A4, TGFbeta and alpha-SMA.

Results In human SSc fibroblasts the gene expression of the relevant markers COL I, FN and S100A4 resulted of 107 RNA copies for each gene. Interestingly, in the same tested fibroblasts, the profibrotic alpha-SMA gene expression (marker of myofibroblasts) was similarly found highly expressed, with a result of 107 gene copies. On the contrary, TGFbeta showed a much lower gene expression (103 copies) compared to the other investigated genes.

Conclusions In human SSc cultured dermal fibroblasts, the gene expression of ECM proteins (COL I and FN), was found associated with a relevant gene expression of S100A4 and alpha-SMA, confirming their myofibroblast phenotype, as highly differentiated. Interestingly, TGFbeta gene appears to be less expressed. It could be concluded that myofibroblasts from the SSc skin mainly undergo the effects of the tissutal TGFbeta, since it seems that they do not contribute to its further production once differentiated.


  1. Cutolo M. et al. J Rheumatol 2015;42:3.

  2. Brunasso A.M. et al. F1000Research 2016;5:723.

  3. Hinz B et al. Am J Pathol 2012;180:1340–55.

  4. Dumoitier N. et al. Arthritis Rheumatol 2016 [Epub ahead of print].


Disclosure of Interest None declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.